
    
      A double-blind, multicenter, randomized, saline-controlled trial (RCT) that will evaluate the
      efficacy of a single dose of Autologous Protein Solution (APS) in patients with symptomatic
      osteoarthritis (OA) of the knee who have not been able to get satisfactory pain relief with
      prior treatment.
    
  